XML 155 R35.htm IDEA: XBRL DOCUMENT
v3.25.4

Segment Information (Tables) | 9 Months Ended | 12 Months Ended
--- | --- | ---
Sep. 30, 2025 | Dec. 31, 2024
Segment Information [Abstract] |  |
Schedule of Consolidated Statements of Operations | The following table includes revenue, significant veterinary clinic and hospital operating expenses, and Adjusted Clinic EBITDA for the Company’s clinics, reconciled to the consolidated amounts included in the Company’s consolidated statements of operations:
|  | For the three months ended September 30, |  |  | For the nine months ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Revenue |  |  |  |  |  |  |  |  |  |  |  |
Service revenue |  | $ | 3,138,670 |  |  | $ | 2,969,748 |  |  | $ | 9,074,965 |  |  | $ | 9,735,585 |
Product revenue |  |  | 1,177,462 |  |  |  | 1,079,277 |  |  |  | 3,163,910 |  |  |  | 3,535,388 |
Total Clinics level revenue |  |  | 4,316,132 |  |  |  | 4,049,025 |  |  |  | 12,238,875 |  |  |  | 13,270,973 |
Operating expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of service revenue (exclusive of depreciation and amortization, shown separately below) |  |  | 2,678,940 |  |  |  | 2,568,085 |  |  |  | 7,253,536 |  |  |  | 7,705,972 |
Cost of product revenue (exclusive of depreciation and amortization, shown separately below) |  |  | 850,153 |  |  |  | 854,921 |  |  |  | 2,507,227 |  |  |  | 2,807,025 |
General and administrative expenses |  |  | 610,629 |  |  |  | 65,093 |  |  |  | 2,015,056 |  |  |  | 2,034,074 |
Total Clinics level expenses |  |  | 4,139,722 |  |  |  | 3,488,099 |  |  |  | 11,775,819 |  |  |  | 12,547,071 |
Adjusted Clinics EBITDA |  | $ | 176,410 |  |  | $ | 560,926 |  |  | $ | 463,056 |  |  | $ | 723,902 |
Reconciliation of Adjusted Clinics EBITDA to net income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | 330,498 |  |  |  | 340,167 |  |  |  | 864,293 |  |  |  | 1,048,290 |
Interest income |  |  | (4 | ) |  |  | (44 | ) |  |  | (25 | ) |  |  | (46 | )
Interest expense |  |  | 559,111 |  |  |  | 1,254,149 |  |  |  | 1,385,891 |  |  |  | 2,801,491 |
Debt extinguishment loss |  |  | - |  |  |  | - |  |  |  | 689,411 |  |  |  | 1,587,862 |
Other income (expenses) |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 4,768 |
Gain on sale of business |  |  | - |  |  |  | (467,049 | ) |  |  |  |  |  |  | (467,049 | )
Corporate general and administrative |  |  | 1,813,078 |  |  |  | 2,923,029 |  |  |  | 5,499,364 |  |  |  | 6,046,125 |
Net Income |  | $ | (2,526,273 | ) |  | $ | (3,489,326 | ) |  | $ | (7,975,878 | ) |  | $ | (10,297,539 | )
| The following table includes revenue, significant veterinary clinic and hospital operating expenses, and Adjusted Clinic EBITDA for the Company’s clinics, reconciled to the consolidated amounts included in the Company’s consolidated statements of operations:
|  | For the year ended December 31, |
|  | 2024 |  |  | 2023 |
Revenue |  |  |  |  |  |
Service revenue |  | $ | 12,188,526 |  |  | $ | 11,879,934 |
Product revenue |  |  | 4,403,583 |  |  |  | 4,795,459 |
Total Clinics level revenue |  |  | 16,592,109 |  |  |  | 16,675,393 |
Operating expenses |  |  |  |  |  |  |  |
Cost of service revenue (exclusive of depreciation and amortization, shown separately below) |  |  | 9,736,282 |  |  |  | 9,700,963 |
Cost of product revenue (exclusive of depreciation and amortization, shown separately below) |  |  | 3,563,279 |  |  |  | 3,420,515 |
General and administrative expenses |  |  | 2,688,157 |  |  |  | 3,056,702 |
Total Clinics level expenses |  |  | 15,987,718 |  |  |  | 16,178,180 |
Adjusted Clinics EBITDA |  | $ | 604,391 |  |  | $ | 497,213 |
Reconciliation of Adjusted Clinics EBITDA to net loss |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | 1,308,619 |  |  |  | 1,252,539 |
Gain on sale of business |  |  | (467,049 | ) |  |  | - |
Loss on debt extinguishment |  |  | - |  |  |  | 16,105 |
Interest expense |  |  | 3,098,237 |  |  |  | 2,538,710 |
Loss on debt modification |  |  | 2,134,218 |  |  |  | 927,054 |
Beneficial conversion feature |  |  | - |  |  |  | 4,137,261 |
Other income (expenses) |  |  | 4,768 |  |  |  | (1,134 | )
Corporate general and administrative |  |  | 8,733,195 |  |  |  | 6,419,585 |
Impairment expense |  |  | 56,664 |  |  |  | - |
Net Loss |  | $ | (14,264,261 | ) |  | $ | (14,792,907 | )

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration